Xgeva售价多少呢？

How much does it cost? Xgeva is on the market in multiple regions, and the price in different regions is different. The price of Xgeva in the United States is: Prolia, pharmaceutical manufacturer: Amgen/American Amgen Biopharmaceuticals, pharmaceutical specification: 60mg/1ml tube/box, price: $1,169.98/unit: US dollars; pharmaceutical specification: 120mg/1.7ml bottle/box; price: $2,391.11/unit: US$. The specification of Xgeva exported to Türkiye from the United States is 125mg/1ml tube/box, and the price is about 3,000$, which is the most cost-effective one.

Xgeva is a human monoclonal antibody, RANKL inhibitor, indicated for the treatment of osteoporosis, therapy-induced bone loss, metastasis to bone, and giant cell tumor of bone. Works by preventing the development of osteoclasts, cells that break down bone (bone resorption). Developed by biotech company Amgen, Xgeva reduces the risk of fractures in cancer patients.

On May 28, 2010, the European Commission approved the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. On June 2, 2010, Xgeva, trade name Prolia, was approved by the United States (FDA) for use in postmenopausal women with the risk of osteoporosis. On October 26, 2018, Amgen Pharmaceuticals submitted a marketing application in China, with the application name: denosumab. On May 23, 2019, China’s National Medical Products Administration announced conditional approval of the import registration application for (Xgeva) Denosumab Injection (English name: Denosumab Injection). Xgeva will be used to treat adults and skeletally mature adolescent patients with unresectable giant cell tumors of bone or for whom surgical resection would result in severe functional impairment.